Risk-adapted strategy for the management of febrile neutropenia in cancer patients.
BACKGROUND
Among patients who develop fever and neutropenia after having received cancer chemotherapy, we have to distinguish at least three categories of risk levels for complications and death: patients at low risk and eligible for oral treatment and possibly outpatient management, patients at low risk who require intravenous therapy, and patients at higher risk.


CONCLUSIONS
The Multinational Association for Supportive Care in Cancer scoring system identifies patients at low risk (<5%) of severe complications with very low mortality (<1%) during an episode of febrile neutropenia; this group represents roughly 70% of an unselected population of patients with febrile neutropenia. A significant percentage (approximately 50%) of these patients are eligible for treatment with orally administered antibiotics and can be discharged early and safely from the hospital after a short (24-48 h) observation period.
Klastersky
Jean
J
Institut Jules Bordet, Oncology Program for the Brussels Public Hospitals, Brussels, Belgium.
Paesmans
Marianne
M
D000935:Antifungal Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000276:immunology; D001530:Belgium; D019468:Disease Management; D005334:Fever / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy; D020379:Risk Adjustment
D000935:Antifungal Agents; D000970:Antineoplastic Agents